High interstitial fluid pressure — an obstacle in cancer therapy

The 2004 Nature Reviews Cancer synthesis that established elevated tumour interstitial fluid pressure (IFP) as a clinical- oncology variable in its own right. The author quartet is Swedish and senior: Carl-Henrik Heldin is the long-time Director of the Ludwig Institute for Cancer Research, Uppsala Branch (a position he held for over thirty years), and a major figure in growth- factor signalling; Kristofer Rubin and Arne Östman were also at Uppsala / Ludwig; Kristian Pietras was the most junior of the four and has since built a substantial cancer-microenvironment programme at Lund. The collaboration is the senior-Swedish-tumour- biology programme writing the field's standard review.

Published in Nature Reviews Cancer in October 2004, the piece is a synthesising review consolidating the empirical literature on tumour IFP as a barrier to drug delivery. The substance: solid tumours characteristically show interstitial fluid pressure ten to forty times normal tissue values, driven by abnormal vasculature, dense and contracted interstitial matrix, and disrupted lymphatic drainage. The elevated pressure creates an outward convective flow gradient that limits transcapillary delivery of therapeutic agents — chemotherapeutics, antibodies, nanoparticles — and contributes to the poor drug response of many solid tumours. The proposed solution is pharmacological IFP- lowering through signal-transduction antagonists targeting PDGF, TGF-β, and related pathways.

The piece sits as the founding clinical-translational review of the interstitium-and-cancer programme. Where Wiig and Swartz 2012 gives the basic-physiology synthesis, this 2004 review establishes the clinical framing that subsequent work — Munson on interstitial flow in glioblastoma, Swartz and Lund 2012 on tumour-lymphatic mechanobiology — has extended. The hyaluronidase clinical trials of the 2010s (PEGPH20 in pancreatic cancer) are direct downstream applications of this review's IFP-lowering hypothesis.

The stake is scientific and clinical-translational. Heldin and collaborators were arguing for a specific therapeutic direction — IFP modulation as a cancer-treatment strategy — with substantial implications for drug development. The Ludwig Institute's research programme has been involved in some of the relevant clinical trials. The review's empirical claims are solidly documented; the therapeutic prescription remains a still- developing programme whose clinical successes have been partial.